Clinical Trial: Phase 1 Safety Study of ALK-001 in Healthy Volunteers
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Phase 1, Open Label, Repeat Dose Study to Investigate the Safety and Pharmacokinetics of 4-week Daily Dosing of ALK-001 in Healthy Volunteers
Brief Summary: This protocol is a phase 1 clinical study to assess the safety and pharmacokinetics of ALK-001 in healthy volunteers. Please contact [email protected] for any questions.
Detailed Summary:
Sponsor: Alkeus Pharmaceuticals, Inc.
Current Primary Outcome: Safety of 4-week daily dosing of ALK-001 in healthy adults. [ Time Frame: 4 weeks ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Alkeus Pharmaceuticals, Inc.
Dates:
Date Received: August 27, 2014
Date Started: April 2014
Date Completion:
Last Updated: March 21, 2015
Last Verified: March 2015